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Abstract
Cancer may act as the etiological agent for natural selection in some genes. This selective pressure would act to reduce the success of
neoplastic lineages over normal cell lineages in individuals of reproductive age. In addition, human’s relatively larger brain and longer lifespan
may have also acted as a selective force requiring new genotypes. One of the most important proteins in both processes is the fatty acid
synthase (FAS) gene involved in fatty acid biosynthesis. A variety of other proteins, including PTEN, MAPK1, SREBP1, SREBP2 and PI are
also involved in the regulation of fatty acid biosynthesis. We have specifically analysed variability in selective pressure across all these genes
in human, mouse and other vertebrates. We have found that the FAS gene alone has signatures indicative of adaptive evolution. We did not find
any signatures of adaptive evolution in any of the other proteins. In the FAS gene, we have detected an excess of non-synonymous over
synonymous substitutions in approximately 6% of sites in the human lineage. Contrastingly, the substitution process at these sites in other
available vertebrates and mammals indicates strong purifying selection. This is likely to reflect a functional shift in human FAS and correlates
well with previously observed changes in FAS biochemical activities. We speculate that the role played by FAS either in cancer development
or in human brain development has created this selective pressure, although we cannot rule out the various other functions of FAS.
D 2005 Elsevier B.V. All rights reserved.
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1. Introduction
Cancer selection describes the situation where cancer acts
as the agent of selection favoring novel mutations over the
wild type (Leroi et al., 2003). While most cancers are
thought of as diseases of the elderly, with their onset being
later than the end of normal reproductive age, some cancers
affect the young and therefore can influence allele frequen-
cies in the next generation. In addition, cancer selection
theory predicts that new mutations would be favored as
animals change their life-histories, evolve new morpholo-
gies and longer lifetimes (Leroi et al., 2003). This theory is
reasonably falsifiable in the sense that there are recognizable
signatures of selection and these should be found in some or
many of the genes implicated in cancer. This can shed light
on the likely historical impact of cancer in human evolution
or at least the historical selective pressures on genes
involved in tumorigenesis.
Fatty acid synthesis is an integral part of all living
systems (Roncari, 1981). Fatty acids are used for energy
storage, synthesis of cell membranes (O’Brien, 1967) and
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generation of cell signaling molecules (Duplus and Forest,
2002). Fatty Acid Synthase (FAS) is one of the largest
vertebrate proteins and consists of a single multifunctional
protein found as a homodimer (Chirala et al., 2001). It is
a key metabolic enzyme catalyzing the synthesis of long
chain saturated fatty acid molecules from acetyl-CoA,
malonyl-CoA and NADPH (Wakil, 1989). An increase in
FAS expression is one of the earliest and most common
events in the development of many human cancers and is
closely linked to malignant transformation and to tumor
virulence (Kumar-Sinha et al., 2003). In contrast to
normal cells that preferentially use dietary fatty acids
(Zhou et al., 2003), human cancer cells are dependent
upon fatty acid synthesis for growth and survival.
Inhibiting fatty acid synthesis by inhibiting FAS in
cycling cancer cells leads to cell death, while normal
cells survive (Pizer et al., 2001; Zhou et al., 2003). Over-
expression of FAS in cancer cells is both linked to the
inactivation of PTEN (phosphatase and tensin homolog)
and to increases in epidermal growth factor signaling (Van
de Sande et al., 2002). These act in major part through
the mitogen-activated protein kinase and phosphatidylino-
sitol-3 kinase signaling cascades (MAP and PI-3K,
respectively) (Yang et al., 2002). Cellular cholesterol
and Fatty acid metabolism in mammals is controlled by
Sterol Regulatory Element Binding Proteins (SREBPs)
(Nohturfft et al., 1999). By inhibiting MAP and PI-3
kinases, SREBP1 levels are downregulated and tran-
scription of the FAS promoter is decreased, thereby
reducing fatty acid synthesis in cancer cells (Yang et al.,
2002, 2003). FAS regulation is likely to be of major
significance in the treatment of cancers (Kumar-Sinha et
al., 2003; Qiao et al., 2003). If positive selection for novel
FAS genotypes has been a major contributor to the
evolution of the human lineage, it should be possible to
identify this situation. Positive selection for new geno-
types is caused by selection for new phenotypes. One
theory in particular — the Ffat utilization hypothesis_
(Horrobin, 1998, 1999) is interesting as it proposes that
changes in fatty acid synthesis may have been a major
feature of human evolution. Here we will examine a
number of genes with roles central to fatty acid
metabolism and cancer.
The Neutral and Nearly Neutral theories of molecular
evolution contend that the majority of sequence change is
dictated by random genetic drift (Kimura, 1983). If this is
true, then positive selective pressures that have been
capable of overcoming random genetic drift are likely to
be very rare, but important. Adaptive evolution of colubine
lysozyme genes permits foregut fermentation in these
Table 1
Genes, accession numbers and lengths of alignments used in this study
Gene name Human acc Mouse acc Other species_acc Length
Fatty Acid Co-Enzyme A ligase (F.A.C.) (E.C.6.2.1.3) L09229 BC056644 RAT_D90109 2196
AB033899 BC031544 RAT_AB012933
BC026161 BC022959 RAT_D10041
AF030555 AJ243502 RAT_D85189
D89053 BC031529 RAT_D30666
Acyl-Co-enzyme A Dehydrogenase (A.C.A.D.) (E.C.1.3.99.13) M74096 U21489 PIG_D89478 1290
Liver Carnitine Palmitoyltransferase 1 (L.C.P.T.) (E.C.2.3.1.21) BT009791 BC054791 SHEEP_Y18387 2319
Liver Fatty Acid Binding Protein (LFABP) M10617 BC009812 PIG_X77640 381
Mitogen-Activated Protein Kinase-2 (MAPK2) (E.C.2.7.1.37) M84489 M64300 COW_Z14089 1089
FROG_M60977
Phosphatidylinositol-3 kinase (PI-3K) D30036 U96725 RABBIT_U12558 813
RAT_M25758
Sterol Regulatory Binding Protein 1 (SREBP1) U00968 BC056922 RAT_AF286470 3471
HAMSTER_U09103
CHICKEN_AY029224
Sterol Regulatory Binding Protein 2 (SREBP2) U02031 AF374267 HAMSTER_U12330 3432
CHICKEN_AJ414379
Fatty Acid Synthase (F.A.S.) (E.C. 2.3.1.85) U26644 AF127033 CHICKEN_J03860 7581
RAS-related C3 botulinum toxin substrate 3 (RAC3) BT019443 AB040819 RAT_AY491395 576
COW_AF175262
ZEBRAFISH_BC044538
Dicarbonyl/l-xylulose reductase (DCXR) BT006881 D89656 HAMSTER_AB045204 732
RAT_AB061719
GUINEAPIG_AB061720
FROG_BC062504
Cop9 signalosome complex subunit 1 (GPS1) U20285 BC003350 ORANGUTAN_CR861104 1581
RAT_BC061746
CHICKEN_AJ719637
Beta-1,3-N-acetylglucosaminyltransferase radical fringe (RFNG) AF108139 U94350 RAT_AB016486 1143
CHICKEN_GGU91850
ZEBRAFISH_AF510993
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animals and is responsible for a functional shift in the
protein, specifically an increased pH tolerance and
resistance to digestion by pepsin (Messier and Stewart,
1997). Positive selection has previously been reported in
proteins with more central roles in metabolism, including
extensive studies on the cytochrome oxidase (COX)
complex in primates (Goldberg et al., 2003). The adaptive
evolutionary events on the COX complex have been
viewed as part of a series of coadaptive changes that
optimized the anthropoid biochemical machinery for
aerobic energy metabolism and alternatively the evolution
of an expanded neocortex in anthropoid primates. There is
strong evidence that the tumor suppressor gene BRCA1 has
undergone positive selection in the primate lineage, to a
lesser extent along the chimpanzee lineage, but most
prominently along the human lineage (Yang and Nielsen,
2002). During human evolution the BRCA1 tumor sup-
pressor gene has been under selective pressure for change
perhaps conveying longevity to its host also showing the
selective pressure cancer plays in evolution. This growing
body of evidence indicates that positive selection was
sufficiently strong on many occasions to overcome random
genetic drift. These positive selection events are usually
correlated with functional shifts in those proteins in which
we find these changes.
In a comparative analysis of human and chicken FAS
protein activities, it has been reported that there are some
significant differences in the biochemical activities of
these proteins (Jayakumar et al., 1995). The overall
activity of FAS is much lower in humans than in chicken,
with the FAS partial activities varying somewhat in their
activities. For instance, the h-ketoacyl synthase activity is
threefold lower in the human lineage and the enoyl
reductase activity is twentyfold higher (Jayakumar et al.,
1995).
In this study we sought to analyse variation in selective
pressures across sites and lineages in a group of genes that
are known to be involved in effecting and regulating fatty
acid biosynthesis. Specifically, we wished to know if
positive selection could have been a driving force in amino
acid substitution in this cohort of proteins.
2. Materials and methods
2.1. Data assembly
We have created alignments of nine families of genes
with documented roles in fat metabolism and in a variety
of cancers. We have also analysed four neighboring genes
of the FAS gene in the human and mouse genomes to
determine if the GC content at this locus is influencing
the evolutionary rate. These genes and their accession
numbers and alignment lengths are listed in Table 1. In all
cases, there was at least one human and one mouse
sequence. These sequences were available in both the
GenBank and Swissprot databases, thereby minimizing the
possibility of using incorrect sequences. All alignments
were carried out at the amino acid level using ClustalX
1.81 (Thompson et al., 1994), and gap positions were
placed into the nucleotide sequences according to where
they were found in the protein alignment. The Fatty Acid
Co-enzyme A ligase (FAC) data represents a multigene
family. The FAC phylogenetic tree was reconstructed
using the neighbor joining method and protein distances
calculated from the PHYLIP package (Felsenstein, 1993),
see Fig. 1.
2.2. Description of models employed in the Likelihood Ratio
Test
The Likelihood Ratio Test (LRT) using nested models
of sequence evolution was used to evaluate a variety of
models of codon sequence evolution (Yang, 1997). The
LRT proceeds by comparing nested models of sequence
evolution. These models usually allow for variable non-
synonymous to synonymous (Dn /Ds or x) ratios among
sites, along different branches of a phylogenetic tree or in
combination. These models imply that there are a variety
of classes of sites in a given set of aligned sequences and
the LRT provides a method of identifying the model that
best describes the evolution of the set of sequences. One
Fig. 1. Phylogenetic reconstruction of the Fatty Acid Co-enzyme A ligase
(FAC) family. Branches labeled as foreground in the analyses are numbered
1 to 5.
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model is usually constrained so that x!1. The more
general model allows at least one class of sites to exist
where the x value is dependent on the data. In those
cases where the x value exceeds unity and the resulting
increase in the likelihood score is significant, we can
conclude that positive selection has occurred. In order to
ascertain significance of difference in likelihood score we
can compare the likelihood statistic 2 Dl with vv
2, where v
is the number of degrees of freedom and corresponds with
the number of free parameters.
The simplest model (fewest free parameters) is called
M0. In this model it is assumed that there is a single x value
at all sites and across all lineages. This corresponds to the
Goldman and Yang model (Goldman and Yang, 1994).
Model M1 assumes that there are two classes of sites —
those with an x value of zero and those with an x value of
1. Model M2 allows for three classes of sites — one with an
x value of zero, one with an x value of one and one with an
x value that is not fixed to any value. Given the relationship
between M1 and M2, they can be tested for the significance
of the difference of the fit of these two models using an LRT
with df =2. Model M3 allows all x values to vary freely.
There are two variants of this model employed in this
analysis. The first is where there are two classes of sites that
are free to vary (k =2) and the second is where there are
three classes of sites (k =3). M3 (k =2) can be tested for its
fit against M0 with df =2. M3 (k =3) cannot be tested
against any of the other models presented here using an
LRT, however, its empirical comparison with M3 (k =2) can
be interesting if the likelihood score is better.
We have also employed a number of models that use
discrete approximations to continuous distributions in order
to model variability in x at different sites. The first of these,
M7, assumes that variation inx follows a beta distribution. A
total of ten classes of sites are assumed to exist and their x
values are constrained to be between zero and one. The
second model, M8, allows the existence of another class of
site where the x value is allowed to be greater than unity. M8
and M7 can be compared with one another using the LRT
with df =2.
Finally, we used two models that allow the x value to
vary across sites and across different lineages. The first of
these, Model A, is a lineage-specific extension of M1 and
the second, Model B, is a lineage-specific extension of M3
(k =2). Both of these branch-site models can be compared
with their site-specific counterparts using the LRT with
df =2. We can attempt to identify those individual sites
where positive selection has occurred using the empirical
Bayes approach implemented in the software (Yang and
Nielsen, 2002).
For all models used in the analysis where x is estimated
from the data, a variety of starting x values were used for
the calculation of likelihood estimates. This ensures that the
global minimum is reached. The significance level for
positively selected sites is taken as greater than 5% of any
given alignment throughout the manuscript.
3. Results and discussion
3.1. FAS gene analysis
The alignment of the FAS gene resulted in 7581 aligned
nucleotide positions (2527 codon positions). Our initial
analysis involved using the original maximum likelihood
codon-based model (Goldman and Yang, 1994). For this
model, x is assumed to be constant for all sites and all
positions and was estimated to be 0.116, indicating that, on
average, the ratio of non-synonymous to synonymous
substitution is less than unity and reflecting that change in
this protein is overall selected against. Relaxing the
constraint that all lineages should have the same x value,
the human lineage was allowed to have a different x value
to the other two lineages. In this case the estimated values
for x in the human and mouse lineages were 0.099 and
0.118 for the Fbackground_ lineages, respectively, and 0.206
and 0.09 for the human and mouse Fforeground branches_,
respectively, again suggesting strong purifying selection on
average. The consequent decrease in the log-likelihood
score was significant ( p <0.05).
We then examined models of sequence evolution where
the x value is allowed to vary from site to site. These are
indicated using the notation M1 to M8 in Table 2. M1,
which has two classes of sites, one class where the x value
is fixed at zero, implying that changes at these sites are
unable to occur, and another class of sites where the x value
is fixed at unity. This model is the poorest fit to the data of
any model we have examined (ln L="28,289.8085). Model
M2, allows an additional class of sites to exist, with x
estimated from the data. This model was a much better fit to
the data with the likelihood score increasing by more than
587 units. This indicates that models that allow variation
across the alignment provide a better description of the data
than models that do not.
The next two models use an unconstrained discrete
distribution in order to model variability at different sites in
the alignment. The first of these models, M3 (k=2) allows
two classes of sites to exist in the alignment and does not
constrain any x value. This model results in a likelihood
score (ln L="27,707.431) that is not lower than the score
obtained from model M2 (ln L="22,702.463). However,
when we allow three classes of site (M3 k =3), we recover a
likelihood score that is better than the simpler model (M3
k =2) by greater than seven likelihood units. Both models
are significantly better than model M0 (2 Dl =748,
p <0.0005, df =2 for k =2 site classes, and 2 Dl=746 with
p <0.0005 and df =4 for k =3 sites classes). Of interest is
model M3 k =3. This is the site-specific model that gives the
highest likelihood. It also indicates that the third class of
sites has an x value that is far less than unity (x =0.609).
This proportion of sites is approximately 12%. Model M7
does not allow for positively selected sites, but allows
variation in x across sites in the interval (0,1). The
likelihood score for this model is not particularly high (ln
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L="27,702.395). However, model M8 is not significantly
better (2 Dl =2.3). It is important to remember here that
these models do not allow for lineage-specific evolutionary
rates and as the preliminary analysis with the 2 ratio model
indicated there may be a lineage-specific rate variation in
the FAS gene.
The next category of models that were used were those
branch-site models described by Yang and Nielsen (2002).
These are designated FModel A_ and FModel B_ in Table 1.
The human branch and mouse branch were labeled in turn
as ‘‘foreground’’ for both Model A and Model B with the
rest of the phylogeny treated as ‘‘background’’. Model A is
an extension of the site-specific neutral model (M1) and can
be compared with it using a v2 test with 2 degrees of
freedom. The difference in log-likelihood value is signifi-
cant in both human and mouse cases (2 Dl=209, p=0 for
human, 2 Dl =239, p =0 for mouse). This indicates that site-
and lineage-specific models provide a better description of
the data, indicating that the molecule has evolved differently
in different lineages.
Model B is the model that results in the best likelihood
score of any model examined. It is significantly better than
the discrete model M3 (k =2), with which it can be
compared using a v2 test (2 Dl=155.957, p =0, df =2 for
human). This model also indicates that some sites are
evolving under the influence of positive selection, specif-
ically in the human lineage. A total of 6% of sites have an x
value of 5.84 in the human lineage. This is in contrast to
model M3 (k =2) itself and M3 (k =3) neither of which
indicate site-specific positive selection. Model B for the
mouse lineage is also significantly better than M3 (k =2) (2
Dl=11.75, p <0.005, df =2), this model indicates strong
purifying selective pressure in the mouse lineage for this
protein. The lowest likelihood score of all models tested is
for model B with the human branch labeled as foreground.
The inference is that the molecule has been under an
increased positive selective pressure in the human lineage.
Interestingly, of the 15 sites that have a posterior
probability greater than 0.95 of being in the class of sites
under positive selection, many are very close to known
active sites of the protein, see Fig. 2(b). Five substitutions
are of particular interest. One of the substitutions identified
as having a high likelihood of being under positive selection
in the human lineage ( p<0.05) occurs at position 877 and is
located adjacent to the h-hydroxyacyl dehydratase active
site of this protein at position 876. This is a change from a
polar cysteine residue (in chicken, mouse, rat and cow) to a
non-polar Threonine (in human). Although we can only
speculate on the functional significance of this change, its
radical nature and close proximity to one of the most
important residues in the entire protein make this an
interesting event.
In addition, two substitutions occur at sites that are close
to the Malonyl transferase dehydratase active site at position
580 that is responsible for the conversion of malonyl-CoA
and ACP to CoA and malonyl-ACP. This is the initial
reaction in de novo fatty acid synthesis, see Fig. 2(a). These
substitutions, which are located at positions 587 and 588
involve a change from a polar, neutral Tyrosine (in chicken,
mouse, rat and cow) to a non-polar, neutral Valine (in
Table 2
Parameter estimates for fatty acid synthase gene
Model p ln L Estimates of parameters Positively selected sites
M0: one ratio 1 "28,081.5924 x =0.116 None
Site-specific
M1: neutral 1 "28,289.809 p0=0.53 Not allowed
M2: selection 3 "27,702.463 p0=0.43, p1=0.05, ( p2=0.51), x2=0.19 None
M3: discrete (k =2) 3 "27,707.431 p0=0.62, ( p1=0.38), x0=0.02, x1=0.34 None
M3: discrete (k =3) 5 "27,699.505 p0=0.41, p1=0.47, p2=0.12, x0=0, x1=0.16, x2=0.61 None
M7: beta 2 "27,702.395 p =0.38, q =2.116 Not allowed
M8: beta and omega 4 "27,701.241 p0=0.76, p =0.74, q =3.03, ( p1=0.24), x =0 None
Branch-specific
Human
Two-ratios 2 "28,061.095 x0=0.099, x1=0.206 None
Mouse
Two-ratios 2 "28,080.279 x0=0.118, x1=0.091 None
Branch-site
Human
Model A 3 "28,184.953 p0=0.533, p1=0.41, ( p2=0.03, p3=0.025), x2=10.52 119>0.5
Mouse
Model A 3 "28,170.318 p0=0.053, p1=0.047, ( p2=0.48, p3=0.42), x2=0.02 None
Human
Model B 5 "27,629.452 p0=0.60, p1=0.34, ( p2=0.04, p3=0.02), x0=0.02, x1=0.32, x2=5.84 101>0.5
Mouse
Model B 5 "27,701.555 p0=0.37, p1=0.22, ( p2=0.26, p3=0.15), x0=0.02, x1=0.36, x2=0 None
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human) and a non-polar, tiny Alanine (chicken, mouse, rat
and cow) to an large, basic Arginine (in human) respec-
tively. At position 2155, which is four residues away from
the phosphopantetheine binding site, there is another radical
substitution from a Glutamate to Proline in the human
lineage. The last replacement substitution that occurs in this
protein is a change from a neutral, non-polar Valine to a
basic, large Arginine at position 2501, on the boundary of
the last domain (Thioesterase) of FAS. However it has been
shown that positions identified in this way should be treated
with some caution (Zhang, 2004).
The GC content between mammals and birds varies
substantially and is known to influence the mutation rate
(Eyre-Walker and Hurst, 2001). The GC3 content of the
human, mouse, rat, cow and chicken for the FAS gene are
85%, 69%, 67%, 82% and 47%, respectively. However, we
have conducted the analysis of the FAS dataset with the
exclusion of the highly divergent chicken sequence. Con-
sidering the FAS data for the mammalian species only the
results indicate that positive selection has influenced the
evolution of this protein, with an estimated x value of 8.98
in the human lineage in 5% of the sites while the mouse
lineage shows evidence of strong purifying selection
(x =0.02). This approach reduces the concern over the use
of a very divergent outgroup species. However, it is
important to keep in mind that the result may be due to
an overall increase in mutation rate in the human lineage.
The genomic location of the FAS gene may be influenc-
ing the mutation rate rather than a shift in selective pressure.
To further investigate this possibility we have analysed four
neighboring genes in the human and mouse genomes. These
genes are listed at the bottom of Table 1, they are RAS-
related C3 botulinum toxin substrate 3 (RAC3), Beta-1,2-N-
acetylglucosaminyltransferase radical fringe (RFNG),
Dicarbonyl/l-xylulose reductase (DCXR), and Cop9 signal-
osome complex subunit 1 (GPS1). The GC3 content for
RAC3 is as follows: Human 85%, Mouse 70%, Rat 56%,
Cow 66% and Zebrafish 52%. The GC3 content for RFNG
is as follows: Human 88%, Mouse 70%, Rat 69%, Chicken
63% and Zebrafish 60%. The GC3 content for GPS1 is as
follows: Human 84%, Orangutan 83%, Mouse 65%, Rat
67%, and Chicken 52%. The GC3 content for DCXR is as
follows; Human 80%, Mouse 70%, Golden Hamster 74%,
Rat 69%, Guinea Pig 70% and Frog 46%. The variation in
GC3 content in these neighboring genes is very similar to
that found in the FAS gene dataset. Analyses of these
neighboring genes will indicate whether the GC3 content in
this region is contributing to the detection of false positive
results. However, we find that the analysis of these genes
does not identify significant levels of positive selection (as
defined as 5% or more of sites in the alignment), thereby
strengthening the argument for positive selection in the FAS
gene (see supplementary information for likelihood scores
and parameter estimates).
3.2. Analyses of interacting proteins
Although the adaptive evolutionary events we see in the
FAS protein may be due to a number of reasons, it is
difficult to ascribe causality to this effect. It is obvious that
primate lineages were influenced by changes in this gene,
with clear evidence for selection for those lineages that had
Fig. 2. (a) A representation of the Fatty Acid Synthase pathway taken from the KEGG web page http://www.genome.ad.jp/kegg/kegg2.html. Outlines the
process of long chain fatty acid synthesis from acetyl-CoA, malonyl-CoA and NADPH. (b) Plot of the exact location of the positively selected sites and where
they occur. The seven classifications across the top of the plot represent the seven major catalytic domains of the protein, the unlabelled 649 amino acid region
in the center of the molecule represent the interdomain (ID). From the left of the chart the following are the domains of FAS, BKA (Beta-ketoacyl synthase),
AMT (Acyl and Malonyl Transferase), Beta-hydroxyacyl dehydratase (DH), ER (Enoyl Reductase), BKAR (Beta-Ketoacyl Reductase), AC (Acyl carrier) and
TE (Thioesterase), each of which has at least one of these sites within its boundaries. The vertical bars represent the active sites and binding sites of FAS. The 5
active sites are as follows: Beta-Ketoacyl synthase at position 161, Malonyltransferase at position 580, Beta-Hydroxyacyl dehydratase at position 876,
Thioesterase at position 2302 and Thioesterase at position 2475. The two binding sites are Pyridoxal phosphate at position 1699 and Phosphopantetheine at
position 2151.
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specific amino acid changes. In order to examine the
possibility that the role of FAS in cancer development was
the cause of positive selection in this gene, we sought to
examine cancer-implicated genes that are known to interact
with FAS. We analysed MAP, PTEN, PI-3K and SREBP1
using the same methods described previously. We wished to
test the hypothesis that if cancer had been a major influence
on primate evolution, there may have been some evidence
for adaptive evolution in many genes involved in the same
processes.
The same models of codon evolution were employed and
the same LRTs were carried out on a variety of gene
sequences whose proteins are known to interact with FAS,
what follows is a description of the maximum likelihood
model that best fit the data for each protein-coding gene.
The finding was that, for the most part, these proteins have
remained under strong purifying selection for the entirety of
the time period under examination. The results of these
analyses are summarized in Table 3 and the likelihood
model for each gene in the study is described below, the full
details of parameter estimates for each of these genes is
given in the supplementary information.
For MAPK1 the best model was the site-specific
selection model M2. Under this model, it is estimated that
there are 95% of the sites under strong purifying selection
with an x value of 0, no sites neutrally evolving, and 5% of
sites with an x value estimate from the data of 0.30. For PI-
3K, the maximum likelihood model is the one ratio model.
Under this model, the average x value for the entire
alignment is 0.025, indicating strong purifying selection.
The maximum likelihood model for ACAD is model B with
the human branch labeled as foreground, and under this
model it is estimated that all sites in the human lineage have
an x value of 0.17444. This indicates strong purifying
selection. The LCPT protein is for the most part under
strong purifying selection (likelihood model is the discrete
model with two site classes) with an x value of 0.0547,
however there are a tiny proportion of the sites (1%)
showing evidence of positive selection with an x value
estimated as 4.08. From Bayesian statistics it is estimated
that 6 sites have greater than 0.5 posterior probability of
being under positive selection, 3 of these sites with strong
support (0.95 posterior probability). The likelihood model
for LFABP is the discrete model with 2 site classes (M3
k =2). Under this model, both proportions of sites and x
values are estimated from the data. It is estimated that 66%
of the sites in the LFABP protein are under purifying
selection with an x value of 0.019 and 26% of sites are
evolving almost neutrally with an x value of 0.8. The
likelihood model for SREBP1 is the one ratio model with x
estimated as 0.247 for the entire alignment. For the SREBP2
protein the likelihood model is the discrete model with three
site classes. The majority of the SREBP2 protein is under
strong purifying selection with 60.5% of the alignment
under strong purifying selection (x =0.0001), and 39.2% of
the alignment under slightly weaker purifying selection with
an estimated x value of 0.201. There is a very tiny
proportion, only 0.03% of the protein estimated to have an
x value of 5.9. Finally the results of the analysis of the FAC
protein family indicated that the site-specific model for the
data was the discrete model with 3 site classes showing
purifying selection of various strengths across the protein.
There are 25% of sites with an x value estimated as 0.009,
51% of sites with an x value estimated as 0.09 and 23% of
the protein has an x value estimated as 0.31. The
phylogenetic tree used in the analysis of FAC is shown in
Fig. 1. Each of the labeled branches was analysed in turn.
For branches 1, and 3 on the phylogeny the likelihood
model is model B, showing strong purifying selection across
98.5% and 98% the protein for branches 1 and 3,
respectively. However, for both branch 1 and 3 there are
1.5% and 2% of the protein, respectively, showing signa-
tures of positive selection.
The results show that considering all the known proteins
that interact with FAS in the cancer-causing pathway the
dominant selective pressure is purifying and this has been
the case for the entirety of the time period under
examination. None of these other proteins have any
substantial evidence of positive selection at an appreciable
number of sites.
Table 3
Genes known to interact with FAS and its role in Cancer, or metabolism
Model MAPK1 PI ACAD LCPT LFABP SREBP1 SREBP2 FAC FAS
M0: one ratio None None None None None None None None None
2 ratios None None None None None None None None None
M2: selection None None None None None None None None None
M3: discrete k =2 None None None None None None None None None
M3: discrete k =3 None None None None None None None None None
M8: beta and omega None None None None None None None None None
Model A None 1 None None None None None None None
Model B None 1 None None None None None None 101
The left-most column represents those models used and described in the Materials and methods section which allow for positive selection. For each gene, the
results of adaptive evolution analysis using maximum likelihood analysis is listed in terms of whether sites were identified as having high probability of being
in a class of sites likely to be under positive selection. FAS is the only gene which shows a significant number of sites under positive selection. Using Model B
which best fits the data, 101 sites are identified with probability greater than 0.5 of being under positive selection, 15 of these have extremely high posterior
probabilities of greater than 0.95.
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For this protein interaction network, the FAS protein is
unique in terms of its evolutionary history (see Table 3).
The number of vertebrate genes displaying evidence of
adaptive evolution remains small, e.g., ape cytochrome c
oxidase (Goldberg et al., 2003), lysozyme of the foregut
fermenters (Messier and Stewart, 1997), human SRY
(Wang et al., 2002). This low number is either a reflection
of the sparse sampling of vertebrate genomes or because of
the relative infrequency of adaptive events within a
phylum or simply because analyses of this kind have
been rare. However, in this manuscript we report strong
evidence for positive selection in a gene that plays a
central role in metabolism and in the development of many
cancers. Of particular significance is the fact that similar
analyses of a variety of other genes that control the
expression of FAS or interact with it have revealed only
evidence for strong purifying selection in these genes.
Therefore, we suggest that it is not changes in the control
of FAS that has conveyed some advantage, but rather it is
the function of this gene product. Analysis of genes at the
same locus as the FAS gene do not show significant levels
of positive selection, the mutation rate in this gene is
consistent with that of an adaptive evolutionary event
rather than the influence of GC3 content or genome
location.
In summary, the selective pressures on the fatty acid
synthase gene have been highly variable among sites and in
different lineages. Some sites have been under strong
purifying selection throughout the phylogeny, while other
sites appear to be under positive selection only in the human
lineage, with the number of amino acid altering substitutions
in excess of the silent substitutions. The branch leading to
the human lineage is under much stronger positive selective
pressure than the remainder of the phylogeny, with no sites
in the background lineages showing evidence of positive
selection. According to the likelihood model for the FAS
gene, Model B, 101 sites have a probability greater than 0.5
of having been positively selected in the human lineage.
This finding is not incompatible with, yet does not prove the
fat utilization hypothesis (Erren and Erren, 2004; Horrobin,
1998, 1999), which suggests that changes in phospholipid
and fatty acid metabolism played a major role in human
evolution, namely the development of the large human
brain. It is also important to note that this method has
reduced power with such a small sample size, in this case
four or five sequences, and as such to find positive selection
it must show a significantly strong signal (Anisimova et al.,
2001). With more FAS sequences from other species future
analysis will provide even more insight into the evolution of
this central metabolic gene.
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